Oramed Pharmaceuticals (XTAE:ORMP) Other Long-Term Liabilities : ₪0.23 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Other Long-Term Liabilities?

Oramed Pharmaceuticals's other long-term liabilities for the quarter that ended in Mar. 2024 was ₪0.23 Mil.

Oramed Pharmaceuticals's quarterly other long-term liabilities increased from Sep. 2023 (₪0.22 Mil) to Dec. 2023 (₪0.23 Mil) but then declined from Dec. 2023 (₪0.23 Mil) to Mar. 2024 (₪0.23 Mil).

Oramed Pharmaceuticals's annual other long-term liabilities declined from Aug. 2021 (₪0.45 Mil) to Dec. 2022 (₪0.22 Mil) but then increased from Dec. 2022 (₪0.22 Mil) to Dec. 2023 (₪0.23 Mil).

Oramed Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for Oramed Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Other Long-Term Liabilities Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Oramed Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Oramed Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Oramed Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ORMP:USA OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.